HG-10-102-01LRRK2 inhibitor CAS# 1351758-81-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1351758-81-0 | SDF | Download SDF |
| PubChem ID | 58539301 | Appearance | Powder |
| Formula | C17H20ClN5O3 | M.Wt | 377.83 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | LRRK2 inhibitor 1 | ||
| Solubility | DMSO : ≥ 50 mg/mL (132.33 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | [4-[[5-chloro-4-(methylamino)pyrimidin-2-yl]amino]-3-methoxyphenyl]-morpholin-4-ylmethanone | ||
| SMILES | CNC1=NC(=NC=C1Cl)NC2=C(C=C(C=C2)C(=O)N3CCOCC3)OC | ||
| Standard InChIKey | YEVOZZZLKJKCCD-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C17H20ClN5O3/c1-19-15-12(18)10-20-17(22-15)21-13-4-3-11(9-14(13)25-2)16(24)23-5-7-26-8-6-23/h3-4,9-10H,5-8H2,1-2H3,(H2,19,20,21,22) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | HG-10-102-01 is a potent and selective inhibitor of wild-type LRRK2(IC50=23.3 nM) and the G2019S mutant(IC50=3.2 nM)
IC50 Value: 23.3 nM (WT LRRK2); 3.2 nM (LRRK2 G2019S) [1]
Target: LRRK2
HG-10-102-01 maintains the ability to potently inhibit the biochemical activity of wild-type and G2019S mutant LRRK2. HG-10-102-01 exhibited biochemical IC50s of 20.3 and 3.2 nM against wild-type LRRK2 and LRRK2[G2019S], respectively. At a concentration of 10 μM, HG-10-102-01 only inhibited the kinase activities of MLK1 and MNK2 to greater than 80% of the DMSO control. Dose-response analysis revealed inhibition of MLK1 with an IC50 2.1 μM and MNK2 with an IC50 0.6 μM. KinomeScan analysis against a near comprehensive panel of 451 kinases at a concentration of 1 μM resulted in no interactions detected with kinases other than G2019S LRRK2 with the exception of one mutant form of c-Kit (L576P) demonstrating the outstanding selectivity of this inhibitor.
HG-10-102-01 significantly inhibited phosphorylation of wildtype LRRK2 and LRRK2[G2019S] mutant at Ser910 and Ser935 at 0.3-1.0 μM in cell culture, which is approximately the same potency as LRRK2-IN-1 (1). HG-10-102-01 is relatively insensitive to the A2016T mutation which suggests that this mutant will not be useful to validate whether the pharmacological effects of the compound are LRRK2-dependent.
HG-10-102-01 can inhibit phosphorylation of Ser910 and Ser935 of LRRK2 in brain and peripheral tissues following intraperitoneal doses of 50 mg/kg. Further optimization of this chemo-type especially in regards to in vivo half-life will be reported in due course [1]. References: | |||||
HG-10-102-01 Dilution Calculator
HG-10-102-01 Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
HG-10-102-01 is a potent and selective inhibitor of leucine-rich repeat kinase 2 (LRRK2) with the IC50 values of 20.3nM and 3.2nM for wild type LRRK2 and LRRK2 [G1019S], respectively [1].
HG-10-102-01 has shown the potent and selective inhibitor of LRRK2 with the IC50 values of 20.3nM, 153.7nM, 95.9nM and 3.2nM for wild type LRRK2, LRRK2 [A2016T], LRRK2 [G2019S+A1016T] and LRRK2 [G1019S], respectively. In addition, HG-10-102-01 has been reported to induced a dose-dependent inhibition of Ser910 and Ser935 phosphorylation in both wild-type LRRK2 and LRRK2 [G2019S] stably transfected into HEK 293 cells. Moreover, it has been demonstrated that increasing doses of HG-10-102-01 led to similar dephosphorylation of endogenous LRRK2 at Ser910 and Ser935 in HEK293 cells, mouse Swiss 3T3 cells and mouse embryonic fibroblast cells [1].
References:
[1] Choi HG1, Zhang J, Deng X, Hatcher JM, Patricelli MP, Zhao Z, Alessi DR, Gray NS. Brain Penetrant LRRK2 Inhibitor. ACS Med Chem Lett. 2012 Aug 9;3(8):658-662. Epub 2012 Jun 18.
- ONO-4059
Catalog No.:BCC6463
CAS No.:1351635-67-0
- 21,23:24,25-Diepoxy-21,23-dimethoxytirucall-7-en-3-one
Catalog No.:BCN1581
CAS No.:1351617-74-7
- Amooracetal
Catalog No.:BCN6876
CAS No.:1351617-73-6
- Sarpogrelate hydrochloride
Catalog No.:BCC5247
CAS No.:135159-51-2
- H-DL-Ala-OMe.HCl
Catalog No.:BCC2854
CAS No.:13515-97-4
- H-Sar-OMe.HCl
Catalog No.:BCC3335
CAS No.:13515-93-0
- 2',7-Dihydroxy-5,8-dimethoxyflavanone
Catalog No.:BCN4041
CAS No.:1351338-14-1
- Z-Tyr-OMe
Catalog No.:BCC2746
CAS No.:13512-31-7
- Fmoc-Nva-OH
Catalog No.:BCC3302
CAS No.:135112-28-6
- Camelliaside A
Catalog No.:BCN3871
CAS No.:135095-52-2
- kb-NB77-78
Catalog No.:BCC5462
CAS No.:1350622-33-1
- Repaglinide
Catalog No.:BCC2504
CAS No.:135062-02-1
- GNE-7915
Catalog No.:BCC5304
CAS No.:1351761-44-8
- H-Val-OtBu.HCl
Catalog No.:BCC3143
CAS No.:13518-40-6
- Sanggenol P
Catalog No.:BCN4766
CAS No.:1351931-30-0
- 3Beta-acetoxy-eupha-7,25-dien-24(R)-ol
Catalog No.:BCN1580
CAS No.:1352001-09-2
- AMG232
Catalog No.:BCC3992
CAS No.:1352066-68-2
- Schineolignin B
Catalog No.:BCN3623
CAS No.:1352185-26-2
- AZD6738
Catalog No.:BCC6505
CAS No.:1352226-88-0
- Pindolol
Catalog No.:BCC6881
CAS No.:13523-86-9
- Trijuganone C
Catalog No.:BCN3685
CAS No.:135247-94-8
- Pulchinenoside B
Catalog No.:BCN6554
CAS No.:135247-95-9
- EW-7197
Catalog No.:BCC6467
CAS No.:1352608-82-2
- 2''-O-Rhamnosylicariside II
Catalog No.:BCN3464
CAS No.:135293-13-9
Synthesis of [(11)C]HG-10-102-01 as a new potential PET agent for imaging of LRRK2 enzyme in Parkinson's disease.[Pubmed:28223019]
Bioorg Med Chem Lett. 2017 Mar 15;27(6):1351-1355.
The reference standard (4-((5-chloro-4-(methylamino)pyrimidin-2-yl)amino)-3-methoxyphenyl)(morpholino)me thanone (HG-10-102-01) and its precursor (4-((5-chloro-4-(methylamino)pyrimidin-2-yl)amino)-3-hydroxyphenyl)(morpholino)me thanone (desmethyl-HG-10-102-01) were synthesized from 2,4,5-trichloropyrimide and 3-methoxy-4-nitrobenzoic acid with overall chemical yield 49% in four steps and 14% in five steps, respectively. The target tracer (4-((5-chloro-4-(methylamino)pyrimidin-2-yl)amino)-3-[(11)C]methoxyphenyl)(morpho lino)methanone ([(11)C]HG-10-102-01) was prepared from the precursor desmethyl-HG-10-102-01 with [(11)C]CH3OTf through O-[(11)C]methylation and isolated by HPLC combined with SPE in 45-55% radiochemical yield, based on [(11)C]CO2 and decay corrected to end of bombardment (EOB). The radiochemical purity was >99%, and the specific activity (SA) at EOB was 370-1110GBq/mumol with a total synthesis time of approximately 40-min from EOB.
